Turning Point Therapeutics Inc

Turning Point Therapeutics — Technical Presentation (April 2022)

15 slides from Turning Point Therapeutics's technical presentation, Apr 13, 2022

  1. Slide 1: Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC

    Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC Investor Call and Webcast April 13, 2022 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, business strategy and plans, r

  3. Slide 3: Today's Agenda

    Today’s Agenda Introduction Athena Countouriotis, M.D., President & CEO Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC Mohammad Hirmand, M.D., Chief Medical Officer Q&A Panel Athena Countouriotis, M.D., President & CEO Mohammad Hirmand, M.D., Chief Medical Officer Alexander Drilon, M.

  4. Slide 4: TRIDENT-1 study design and analysis populations

    Data cutoff date: 11-Feb-2022 Safety analysis: 380 patients pooled from Phase 1 + 2 (103 from Phase 1 and 277 from Phase 2) Efficacy analysis: Pooled Phase 1 + 2 patients who received at least one dose of repotrectinib with at least 4 months of follow-up, and the majority of responders had at least

  5. Slide 5: EXP-1: ROS1+ TKI-Naïve NSCLC Clinical Activity

    EXP-1: ROS1+ TKI-Naïve NSCLC Clinical Activity Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who

  6. Slide 6: ROS1+ TKI-Naïve NSCLC: Duration of Response by Kaplan Meier

    ROS1+ TKI-Naïve NSCLC: Duration of Response by Kaplan Meier EXP-1 EXP-2 EXP-3 EXP-4 EXP-5 EXP-6 DOR PARAMETER Repotrectinib¹ (N=56) Rozlytrek (entrectinib)² Xalkori (crizotinib)³ Median DOR 95% CI Not mature 15.7 months (13.9, 28.6) 18.3 months (12.7, NE) DOR Range (months) 1.4+-35.1+ 1.8-42.3 - % D

  7. Slide 7: ROS1+ TKI-Naïve NSCLC: Progression Free Survival by Kaplan Meier

    ROS1+ TKI-Naïve NSCLC: Progression Free Survival by Kaplan Meier EXP-1 EXP-2 EXP-3 EXP-4 EXP-5 EXP-6 PFS PARAMETER Repotrectinib¹ (N=71) Rozlytrek (entrectinib)² Xalkori (crizotinib)³ Median PFS 95% CI Not mature 15.7 months (11.0, 21.1) 19.2 months (14.4, NE) PFS Range (months) 0+-40.4+ Not disclos

  8. Slide 8: EXP-2: 1 Prior TKI and 1 Platinum-Based Chemotherapy Clinical Activity

    Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with

  9. Slide 9: EXP-3: 2 Prior TKIs and No Prior Chemotherapy Clinical Activity

    Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with

  10. Slide 10: EXP-4: 1 Prior TKI and No Prior Chemotherapy Clinical Activity

    Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with

  11. Slide 11: Patients with Baseline ROS1 G2032R Solvent Front Mutations

    Note: Of the TKI-pretreated patients, 10 did not have baseline evaluable information to determine presence of ROS1 G2032R solvent front mutation. Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blind

  12. Slide 12: Safety Summary: TRIDENT-1 Phase 2 Combined

    ALL TREATED PATIENTS (N=380) Adverse Reaction TEAES ≥ 15% subjects TRAES ≥ 15% subjects All Grades N (%) Grade 3 N (%) Grade 4 N (%) All Grades N (%) Grade 3 N (%) Grade 4 N (%) Dizziness 230 (60.5) 9 (2.4) 0 209 (55.0) 9 (2.4) 0 Dysgeusia 183 (48.2) 0 0 174 (45.8) 0 0 Constipation 135 (35.5) 1 (0.3

  13. Slide 13: Summary and Next Steps

    TRIDENT-1 topline data for ROS1+ TKI-naïve NSCLC cohorts consistent with potential best-in-class profile cORR of 79% (95% CI: 68, 88), not including 1 patient in an uPR awaiting a confirmatory scan 12-month DOR landmark of 85% and PFS landmark of 82% Early encouraging 18-month DOR and PFS landmarks

  14. Slide 14: Q&A Panel

    Q&A Panel Athena Countouriotis, M.D. President & Chief Executive Officer Mohammad Hirmand, M.D. Chief Medical Officer Alexander Drilon, M.D. Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center

  15. Slide 15: Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC

    Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC Investor Call and Webcast April 13, 2022

Turning Point Therapeutics — Technical Presentation (April 2022) on 6ix